Mihran Shirinian

1.0k total citations
13 papers, 205 citations indexed

About

Mihran Shirinian is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Mihran Shirinian has authored 13 papers receiving a total of 205 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Otorhinolaryngology. Recurrent topics in Mihran Shirinian's work include Head and Neck Cancer Studies (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Lung Cancer Research Studies (3 papers). Mihran Shirinian is often cited by papers focused on Head and Neck Cancer Studies (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Lung Cancer Research Studies (3 papers). Mihran Shirinian collaborates with scholars based in United States, Australia and South Korea. Mihran Shirinian's co-authors include Waun Ki Hong, Isaiah W. Dimery, S S Legha, Scott M. Lippman, Jin S. Lee, Alan Kramer, Adam S. Garden, Randal S. Weber, Lester Peters and Richard Byers and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Head & Neck.

In The Last Decade

Mihran Shirinian

13 papers receiving 199 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mihran Shirinian United States	8	136	109	90	59	32	13	205
H Iro Germany	8	161 1.2×	141 1.3×	157 1.7×	60 1.0×	36 1.1×	28	316
Linda Weeks United States	5	220 1.6×	227 2.1×	91 1.0×	49 0.8×	39 1.2×	5	322
Milovan Dimitrijević Serbia	8	53 0.4×	116 1.1×	108 1.2×	34 0.6×	52 1.6×	37	281
Laura Sala Italy	5	123 0.9×	118 1.1×	144 1.6×	22 0.4×	31 1.0×	10	223
Floyd Christopher Holsinger United States	7	132 1.0×	183 1.7×	226 2.5×	111 1.9×	38 1.2×	14	315
Jemy Jose United Kingdom	8	110 0.8×	186 1.7×	234 2.6×	63 1.1×	19 0.6×	15	298
Anna Sophie Hoffmann Germany	8	111 0.8×	113 1.0×	254 2.8×	24 0.4×	35 1.1×	18	300
Tatsumi Nagahashi Japan	11	128 0.9×	197 1.8×	165 1.8×	75 1.3×	58 1.8×	29	327
Rebecca Hanlon United Kingdom	9	132 1.0×	208 1.9×	278 3.1×	83 1.4×	44 1.4×	15	378
Molly E. Heft Neal United States	8	59 0.4×	53 0.5×	48 0.5×	52 0.9×	51 1.6×	28	195

Countries citing papers authored by Mihran Shirinian

Since Specialization

Citations

This map shows the geographic impact of Mihran Shirinian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mihran Shirinian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mihran Shirinian more than expected).

Fields of papers citing papers by Mihran Shirinian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mihran Shirinian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mihran Shirinian. The network helps show where Mihran Shirinian may publish in the future.

Co-authorship network of co-authors of Mihran Shirinian

This figure shows the co-authorship network connecting the top 25 collaborators of Mihran Shirinian. A scholar is included among the top collaborators of Mihran Shirinian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mihran Shirinian. Mihran Shirinian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Artinyan, Avo, Natalie Seiser, Mihran Shirinian, et al.. (2024). Downstaging after preoperative chemoradiation for locally advanced rectal cancer is associated with better survival than pathologic stage 0–1 disease treated with upfront surgery. International Journal of Colorectal Disease. 39(1). 16–16. 3 indexed citations

Doebele, Robert C., Misako Nagasaka, Viola W. Zhu, et al.. (2020). TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements.. Journal of Clinical Oncology. 38(15_suppl). TPS9637–TPS9637. 10 indexed citations

Senzer, Neil, Alexander S. Rosemurgy, T. Reid, et al.. (2006). The PACT trial: Interim results of a randomized trial of TNFerade biologic plus chemoradiation (CRT) compared to CRT alone in locally advanced pancreatic cancer (LAPC). Journal of Clinical Oncology. 24(18_suppl). 4102–4102. 4 indexed citations

Huber, Martin H., Scott M. Lippman, Steven E. Benner, et al.. (1996). A Phase II Study of Ifosfamide in Recurrent Squamous Cell Carcinoma of the Head and Neck. American Journal of Clinical Oncology. 19(4). 379–383. 14 indexed citations

Huber, Martin H., Scott M. Lippman, Steven E. Benner, et al.. (1995). Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancer. Annals of Oncology. 6(1). 83–85. 1 indexed citations

Huber, Martin H., Isaiah W. Dimery, Steven E. Benner, et al.. (1994). Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck. Investigational New Drugs. 12(4). 327–331. 3 indexed citations

Huber, Martin H., Mihran Shirinian, Scott M. Lippman, et al.. (1994). Phase I/II study of cisplatin, 5-fluorouracil and α-interferon for recurrent carcinoma of the head and neck. Investigational New Drugs. 12(3). 223–229. 8 indexed citations

Shirinian, Mihran, Randal S. Weber, Scott M. Lippman, et al.. (1994). Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: The M. D. Anderson cancer center experience. Head & Neck. 16(1). 39–44. 62 indexed citations

Shirinian, Mihran, et al.. (1992). Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.. PubMed. 19(1 Suppl 1). 49–53. 11 indexed citations

10.

Dimery, Isaiah W., Burke J. Brooks, R Winn, et al.. (1991). Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Journal of Clinical Oncology. 9(11). 1939–1944. 10 indexed citations

11.

Holoye, Paul Y. & Mihran Shirinian. (1991). Adjuvant Surgery in the Multimodality Treatment of Small-Cell Lung Cancer. American Journal of Clinical Oncology. 14(3). 251–253. 2 indexed citations

12.

Lee, Jin S., William K. Murphy, Mihran Shirinian, Arlita Pang, & Waun Ki Hong. (1991). Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy. Cancer Chemotherapy and Pharmacology. 28(3). 199–204. 17 indexed citations

13.

Dimery, Isaiah W., S S Legha, Mihran Shirinian, & Waun Ki Hong. (1990). Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma.. Journal of Clinical Oncology. 8(6). 1056–1062. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact